Satellos Bioscience Inc.
MSLEHealthcareNASDAQBiotechnology · Last scanned Jul 22, 2026
Scan Results
Daily timeframeSatellos Bioscience Inc., a clinical-stage drug development company, focuses on restoring natural muscle repair and regeneration in degenerative muscle diseases in Canada, the United States, and. At a $177.6M market cap, Satellos Bioscience Inc. ranks as a micro-cap company within healthcare. The company uses its proprietary discovery platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo.
Market Cap
$177.6M
Beta
1.17
P/E (TTM)
—
P/E (Fwd)
-2.97
EPS (TTM)
$-1.79
EPS (Fwd)
$-2.87
ROE
-50.7%
ROA
-31.4%
Cash
$69.9M
Total Debt
$0
Free CF
-$15.7M
52W Change
61.8%
Annual Financials
Cash vs Debt
Where MSLE stands vs its 150-day and 200-day moving averages
As of the July 15, 2026 close, MSLE finished 13.48% above its 150-day moving average ($7.94) and 19.65% above its 200-day moving average ($7.53). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is MSLE overbought or oversold?
At the July 15, 2026 close, MSLE's RSI(14) was 77.5, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Satellos Bioscience Inc. reports $69.9M in cash and $0 in total debt. Free cash flow is running at -$15.7M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -50.7% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing MSLE.